Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

The emergence of resistance to the Bcr-Abl inhibitor imatinib mesylate in patients with Philadelphia chromosome-positive (Ph+) leukemia has prompted the development of second-generation compounds active against several imatinib-insensitive mutant forms of Bcr-Abl, including dasatinib (BMS-354825; Br...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Simona Soverini, Sabrina Colarossi, Alessandra Gnani, Fausto Castagnetti, Gianantonio Rosti, Costanza Bosi, Stefania Paolini, Michela Rondoni, Pier Paolo Piccaluga, Francesca Palandri, Panagiota Giannoulia, Giulia Marzocchi, Simona Luatti, Nicoletta Testoni, Ilaria Iacobucci, Daniela Cilloni, Giuseppe Saglio, Michele Baccarani, Giovanni Martinelli
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Ferrata Storti Foundation 2007-03-01
coleção:	Haematologica
Acesso em linha:	https://haematologica.org/article/view/4375
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!